Suicide and schizophrenia: a systematic review of rates and risk factors K Hor, M Taylor Journal of psychopharmacology 24 (4_suppl), 81-90, 2010 | 1190 | 2010 |
A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia J Tiihonen, J Haukka, M Taylor, PM Haddad, MX Patel, P Korhonen American Journal of Psychiatry 168 (6), 603-609, 2011 | 758 | 2011 |
Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial JR Geddes, GM Goodwin, J Rendell, JM Azorin, A Cipriani, MJ Ostacher, ... Lancet 375 (9712), 2009 | 499 | 2009 |
Mortality in schizophrenia: a measurable clinical endpoint CJ Bushe, M Taylor, J Haukka Journal of psychopharmacology 24 (4_suppl), 17-25, 2010 | 300 | 2010 |
“First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects SL Young, M Taylor, SM Lawrie Journal of Psychopharmacology 29 (4), 353-362, 2015 | 236 | 2015 |
Hippocampal volume reduction in schizophrenia: effects of genetic risk and pregnancy and birth complications N Stefanis, S Frangou, J Yakeley, T Sharma, P O’Connell, K Morgan, ... Biological psychiatry 46 (5), 697-702, 1999 | 167 | 1999 |
A new self-rating scale for detecting atypical or second-generation antipsychotic side effects L Waddell, M Taylor Journal of Psychopharmacology 22 (3), 238-243, 2008 | 160 | 2008 |
First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies PM Haddad, M Taylor, OS Niaz The British Journal of Psychiatry 195 (S52), s20-s28, 2009 | 155 | 2009 |
Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine — a123 IBZM single photon emission tomography (SPET) study LS Pilowsky, GF Busatto, M Taylor, T Sharma, T Sigmundsson, DC Costa, ... Psychopharmacology 124, 148-153, 1996 | 147 | 1996 |
Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review L Waddell, M Taylor The British journal of psychiatry 195 (S52), s43-s50, 2009 | 143 | 2009 |
Antipsychotic long-acting injections: mind the gap MX Patel, M Taylor, AS David The British Journal of Psychiatry 195 (S52), s1-s4, 2009 | 117 | 2009 |
Agenesis of the corpus callosum: a United Kingdom series of 56 cases M Taylor, AS David Journal of Neurology, Neurosurgery & Psychiatry 64 (1), 131-134, 1998 | 116 | 1998 |
How to compare doses of different antipsychotics: a systematic review of methods MX Patel, IA Arista, M Taylor, TRE Barnes Schizophrenia research 149 (1-3), 141-148, 2013 | 114 | 2013 |
Antipsychotics and abnormal liver function tests: systematic review KFM Marwick, M Taylor, SW Walker Clinical neuropharmacology 35 (5), 244-253, 2012 | 100 | 2012 |
Hippocampal volume in familial and nonfamilial schizophrenic probands and their unaffected relatives K Schulze, C McDonald, S Frangou, P Sham, A Grech, T Toulopoulou, ... Biological psychiatry 53 (7), 562-570, 2003 | 93 | 2003 |
Brain volumes in adult survivors of very low birth weight: a sibling-controlled study P Fearon, P O’Connell, S Frangou, P Aquino, C Nosarti, M Allin, M Taylor, ... Pediatrics 114 (2), 367-371, 2004 | 88 | 2004 |
NICE CG178 Psychosis and Schizophrenia in Adults: Treatment and Management–an evidence-based guideline? M Taylor, U Perera The British Journal of Psychiatry 206 (5), 357-359, 2015 | 86 | 2015 |
Clozapine: dangerous orphan or neglected friend? S Farooq, M Taylor The British Journal of Psychiatry 198 (4), 247-249, 2011 | 82 | 2011 |
Towards consensus in the long‐term management of relapse prevention in schizophrenia M Taylor, I Chaudhry, M Cross, E McDonald, P Miller, L Pilowsky, ... Human Psychopharmacology: Clinical and Experimental 20 (3), 175-181, 2005 | 80 | 2005 |
Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review M Taylor, KYB Ng Australian & New Zealand Journal of Psychiatry 47 (7), 624-630, 2013 | 79 | 2013 |